Wang Erica T, Pisarska Margareta D, Bresee Catherine, Chen Yii-Der Ida, Lester Jenny, Afshar Yalda, Alexander Carolyn, Karlan Beth Y
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California.
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California.
Fertil Steril. 2014 Dec;102(6):1723-8. doi: 10.1016/j.fertnstert.2014.08.014. Epub 2014 Sep 23.
To determine whether BRCA carriers have a decreased ovarian reserve compared with women without BRCA mutations, because BRCA mutations may lead to accelerated oocyte apoptosis due to accumulation of damaged DNA.
Cross-sectional study.
Academic tertiary care center.
PATIENT(S): A total of 143 women, aged 18-45 years, who underwent clinical genetic testing for BRCA deleterious mutations because of a family history of cancer, were included. The cohort was classified into three groups: BRCA1 carriers, BRCA2 carriers, and women without BRCA mutations (controls). None had a personal history of breast or ovarian cancer.
INTERVENTION(S): None.
MAIN OUTCOME MEASURE(S): The main outcome was serum antimüllerian hormone (AMH) level. Linear and logistic regression models adjusting for age and body mass index (BMI) were performed to determine the association between BRCA mutations and AMH.
RESULT(S): BRCA1 mutation carriers had a significant decrease in AMH levels compared with controls after adjusting for age and BMI (0.53 ng/mL [95% confidence interval (CI) 0.33-0.77 ng/mL] vs. 1.05 ng/mL [95% CI 0.76-1.40 ng/mL]). Logistic regression confirmed that BRCA1 carriers had a fourfold greater odds of having AMH <1 ng/mL compared with controls (odds ratio 4.22, 95% CI 1.48-12.0). There was no difference in AMH levels between BRCA2 carriers and controls.
CONCLUSION(S): BRCA1 carriers have lower age- and BMI-adjusted serum AMH levels compared with women without BRCA mutations. Our results contribute to the current body of literature regarding BRCA carriers and their reproductive outcomes. Larger prospective studies with clinical outcomes such as infertility and age at menopause in this population are needed to further substantiate our findings.
确定与无BRCA突变的女性相比,携带BRCA基因的女性卵巢储备功能是否降低,因为BRCA突变可能因受损DNA的积累导致卵母细胞凋亡加速。
横断面研究。
学术性三级医疗中心。
共纳入143名年龄在18至45岁之间的女性,她们因癌症家族史接受了BRCA有害突变的临床基因检测。该队列分为三组:BRCA1基因携带者、BRCA2基因携带者和无BRCA突变的女性(对照组)。所有参与者均无乳腺癌或卵巢癌个人史。
无。
主要观察指标为血清抗苗勒管激素(AMH)水平。采用调整年龄和体重指数(BMI)的线性和逻辑回归模型来确定BRCA突变与AMH之间的关联。
在调整年龄和BMI后,BRCA1突变携带者的AMH水平与对照组相比显著降低(0.53 ng/mL [95%置信区间(CI)0.33 - 0.77 ng/mL] 对比 1.05 ng/mL [95% CI 0.76 - 1.40 ng/mL])。逻辑回归证实,与对照组相比,BRCA1基因携带者AMH<1 ng/mL的几率高出四倍(优势比4.22,95% CI 1.48 - 12.0)。BRCA2基因携带者与对照组的AMH水平无差异。
与无BRCA突变的女性相比,BRCA1基因携带者经年龄和BMI调整后的血清AMH水平较低。我们的研究结果为当前有关BRCA基因携带者及其生殖结局的文献增添了内容。需要在该人群中开展更大规模的前瞻性研究,观察诸如不孕和绝经年龄等临床结局,以进一步证实我们的研究结果。